ABUS (Arbutus Biopharma) Notes Receivable: $0.0 Mil (As of Mar. 2026)


ABUS Arbutus Biopharma Corp ABUS
51 GF Score
Price $4.57
GF Value $51.39
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Notes Receivable?

Arbutus Biopharma ABUS +3.74% 51 Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $51.39 (Possible Value Trap). The stock has 5 warning signs investors should review.

Arbutus Biopharma's Notes Receivable for the quarter that ended in Mar. 2026 was $0.0 Mil.

Arbutus Biopharma Notes Receivable Related Terms

Arbutus Biopharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Notes Receivable Chart

Arbutus Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arbutus Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ABUS
51GF Score
Arbutus Biopharma Corp ABUS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.0 Mil mean?
Arbutus Biopharma (ABUS) has a Notes Receivable of $0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Notes Receivable too high?
Arbutus Biopharma's current Notes Receivable is $0.0 Mil. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Notes Receivable compare to SPRY and KURA?
Arbutus Biopharma's Notes Receivable of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Notes Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.39, compared to a current price of $4.57 — trading 91.1% below its estimated fair value. The current Notes Receivable is $0.0 Mil. Arbutus Biopharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.57 is trading 91.1% below its estimated GF Value™ of $51.39. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Notes Receivable: $0.0 Mil
  • GF Value™: $51.39 vs. price of $4.57 (91.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score

Get the complete analysis for ABUS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.57
Price
$51.39
GF Value